This real-world study included 433 T2DM patients who were SGLT2-i-naïve, previously uncontrolled on a DPP4-i-based regimen, and initiated on the innovator FDC of empagliflozin and linagliptin, with follow-up in an outpatient setting for at least 12 months. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.